Prucalopride reduces the number of reflux episodes and improves subjective symptoms in gastroesophageal reflux disease: a case series

Table 1 Patients’ characteristics

	Patient 1	Patient 2	Patient 3	Patient 4
Age (years)	49	50	70	40
BMI (Du Bois)	35.9kg/m²	26.8kg/m²	21.9kg/m²	33.8kg/m²
GERD symptoms	Heartburn, regurgitation	Heartburn, regurgitation	Regurgitation	Heartburn, globus, bloating
GERD history	- GERD symptoms >10 years - symptoms persistent to standard PPI	- GERD symptoms >20 years - symptoms persistent to PPI	- GERD symptoms >10 years - symptoms persistent to standard PPI	- GERD symptoms for three months
	- subjective impression of improved symptom control to treatment with ranitidine			- GERD symptoms persistent after successful H. pylori eradication and ongoing standard PPI treatment
				- start prucalopride six months after eradication
Endoscopic findings	Small axial herniation, no reflux lesions	Small axial herniation, ERD LA C	Small axial herniation, no reflux lesions	No axial herniation, no reflux lesions, H. pylori gastritis

BMI – body mass index, ERD – erosive reflux disease, GERD – gastroesophageal reflux disease, H.p. – Helicobacter pylori, LA – Los Angeles classification, PPI – proton pump inhibitor.

ISSN: 1752-1947